Vulvodynia Treatment Market 2018 - 2028 By Key Growth Drivers- Eli Lilly and Company, AstraZeneca Plc., GlaxoSmithKline Plc
Increasing tendency of women who have observed chronic vulvar pain once in a lifetime. If the pain is persistent for more than three months and has no apparent cause, it is called vulvodynia. It is estimated that 16% of women in the U.S. will have Vulvodynia at some point in their lives.
View full press release